← Human Trials & Peer-Reviewed Studies
B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial
Plain-language guide to PMID 20298924 (2010): double-blind randomized controlled trial study of BNP (Nesiritide).
Key Facts
- PMID
- 20298924
- Journal
- Journal of the American College of Cardiology
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Morrow DA et al. (9 authors)
- DOI
- 10.1016/j.jacc.2009.09.068
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at BNP (Nesiritide).
The researchers designed a prospective evaluation of the interaction between B-type natriuretic peptide (BNP) and the effect of ranolazine in patients with acute coronary syndromes (ACS) as part of a randomized, blinded, placebo-controlled trial.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
The researchers measured plasma BNP in all available baseline samples (n = 4,543) among patients with non-ST-segment elevation ACS randomized to ranolazine or placebo in the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thrombolysis In Myocardial Infarction 36) trial and followed them for a mean of 343 days.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
As a double-blind BNP (Nesiritide) study, the assignments were hidden from both participants and investigators until the end.
The comparison arm used a placebo, so changes seen with BNP (Nesiritide) could be set against what happens without it.
BNP elevation was defined as >80 pg/ml.
What Was Measured
The subject headings attached to it are Acetanilides, Acute Coronary Syndrome, Biomarkers, Enzyme Inhibitors, Natriuretic Peptide, Brain, Piperazines and Ranolazine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of BNP (Nesiritide).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2010 (Journal of the American College of Cardiology), a journal based in United States.
More context: the BNP (Nesiritide) compound page, all human trials.
Our Notes on the Compound
BNP (Nesiritide): B-type natriuretic peptide, a 32-amino-acid heart hormone; nesiritide (Natrecor) is a recombinant form used in acute heart failure.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.